The trademark application MYOSTRADA was filed by Sarepta Therapeutics, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on November 26, 2020, and it was registered by office on March 5, 2021 without any oppositions.
The application was filed in English (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders
Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production
Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production
Pharmaceutical preparations for gene therapy, gene editing, and genome editing
Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders
Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders
Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders
Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases.